Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C

Table 4 Changes in laboratory parameters before or at the end of treatment (12 wk) among patients who received generic and brand direct antiviral agents

Variable	Period	Generic, mean ± SD	P	Brand, mean ± SD	P
WBC (× 109/L)	wk 0	6.27 ± 3.34	0.15	5.82 ± 2.15	0.005
	EOT	6.67 ± 3.62		6.13 ± 2.40
Haemoglobin (g/dL)	wk 0	12.50 ± 2.52	0.17	12.81 ± 2.12	0.94
	EOT	12.71 ± 2.44		12.81 ± 2.25
Platelets (× 109/L)	wk 0	232.35 ± 108.1	< 0.001	189.01 ± 95.48	< 0.001
	EOT	257.63 ± 113.11		210.85 ± 100.69
PT (sec)	wk 0	14.11 ± 11.93	0.52	13.32 ± 1.88	0.91
	EOT	13.31 ± 8.79		13.30 ± 1.91
PTT (sec)	wk 0	24.16 ± 2.91	0.001	26.20 ± 3.79	0.22
	EOT	23.14 ± 4.25		25.90 ± 3.22
INR	wk 0	1.08 ± 0.18	0.7	1.31 ± 2.22	0.31
	EOT	1.11 ± 0.87		1.12 ± 0.17
Creatinine (μmol/L)	wk 0	66.86 ± 21.07	0.05	89.68 ± 148.85	0.55
	EOT	70.50 ± 31.94		92.05 ± 138.93
Albumin (g/L)	wk 0	41.04 ± 5.11	< 0.001	38.82 ± 6.05	< 0.001
	EOT	42.78 ± 5.46		40.90 ± 5.48
Total bilirubin (μmol/L)	wk 0	17.68 ± 15.62	< 0.001	18.72 ± 18.26	0.004
	EOT	14.30 ± 12.64		15.14 ± 13.74
ALP (U/L)	wk 0	93.31 ± 43.55	< 0.001	102.02 ± 43.79	0.18
	EOT	77.32 ± 32.65		94.79 ± 73.56
ALT (U/L)	wk 0	71.66 ± 57.59	< 0.001	61.96 ± 41.47	< 0.001
	EOT	27.09 ± 33.56		29.09 ± 24.58
gGT(U/L)	w 0	84.44 ± 109.98	< 0.001	101.76 ± 92.69	< 0.001
	EOT	43.48 ± 62.65		50.64 ± 53.37

P values are based on paired t-tests. EOT: End of treatment; WBC: White blood cell count; PT: Prothrombin time; PTT: Partial thromboplastin time; INR: International normalized ratio; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; gGT: Gamma-glutamyl transpeptidase.